Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Studies Previous | All Articles This Week | Next
This article originally posted 29 May, 2009 and appeared in  Issue 470

Tolerx Phase 3 Study

DEFEND is a Phase 3 clinical study of otelixizumab in YOUNG ADULTS with newly diagnosed T1DM.

Otelixizumab is an investigational agent, not yet approved by the FDA for marketing. DEFEND will determine if otelixizumab can help preserve the ability to make endogenous insulin and stop the destruction of the body's cells that make insulin (beta cells). You can find out more at: www.defendagainstdiabetes.com
Advertisement
Advertisement

 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2009 and appeared in  Issue 470

Past five issues: Diabetes Clinical Mastery Series Issue 69 | Issue 611 | Issue 610 | Diabetes Clinical Mastery Series Issue 68 | Issue 609 |

 
Diabetes In Control Advertisers
 
 
Cast Your Vote
Do your type 2 patients not on insulin count their carbs and report back to you?

Navigate Diabetes In Control

Complications CE & CME Clinical Slides Drugs Affecting BG Safety Tools Test Your Knowledge Medications Polls Obesity Case Studies Jobs Interviews

 

Free Weekly Newsletter
Sign up here.

Free CE Available
CE Programs on diabetes




Search Articles On Diabetes In Control